Aripiprazole Tablet
Product Images NDC 68788-8502

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68788-8502). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole Tab Usp 15mg (02a4af27 C83c 4166 950c 7a1cb12d198d 00)

Aripiprazole Tab USP 15 mg tablet label showing the drug name and strength prominently. The label includes warnings about storage temperature, manufacturer's name Alembic Pharmaceuticals Inc., and dosage instructions space for English and Spanish. It mentions the tablet is round, white, and imprinted with 253, with empty fields for lot number, batch number, and expiration date.*

FDA Label Image

Figure 3 (Aripiprazole 3figure)

A pharmacokinetic chart showing fold change and 90% confidence intervals for various drugs and enzymes labeled on the y-axis, such as CYP2D6, CYP2C9, and UGT1A4, with corresponding pharmacokinetic parameters like AUC and Cmax. The x-axis represents change relative to reference without interacting drug, ranging approximately from 0.5 to 3.*

FDA Label Image

Aripiprazole-fig-6.jpg (Aripiprazole Fig 6)

A Kaplan-Meier survival curve graph comparing the proportion of subjects with relapse over time between Aripiprazole and placebo groups. The x-axis shows days from randomization up to 182 days, and the y-axis shows the proportion with relapse from 0 to 1. The graph includes the number of subjects at risk for each group at various time points.*

FDA Label Image

Aripiprazole-fig-7.jpg (Aripiprazole Fig 7)

A line chart depicting the proportion of subjects with relapse over time comparing Aripiprazole and placebo groups. The x-axis represents time in days, with number of subjects at risk shown below the axis. The y-axis shows the proportion with relapse, ranging from 0 to 1. The Aripiprazole group is represented by a solid line consistently showing a lower relapse proportion than the placebo group, depicted by a dashed line.*

FDA Label Image

Aripiprazole-fig-9.jpg (Aripiprazole Fig 9)

A line graph showing the change in YGTSS total tic score from baseline over 8 weeks of treatment. The graph compares three groups: Aripiprazole Low dose, Aripiprazole High dose, and Placebo, depicting least-squares mean change in scores by week. The Aripiprazole groups show a greater decrease in tic scores compared to placebo.*

FDA Label Image

Aripiprazole-figure1.jpg (Aripiprazole Figure1)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals for the area under the curve (AUC) and maximum concentration (Cmax) of Aripiprazole relative to a reference without interacting drug. The graph compares effects of CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam) on Aripiprazole pharmacokinetics.*

FDA Label Image

Figure 2 (Aripiprazole Figure2)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals in AUC and Cmax of dehydro-aripiprazole. The graph compares effects of CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs relative to a reference without interacting drugs.*

FDA Label Image

Figure 4 (Aripiprazole Figure4)

A pharmacokinetic chart showing fold change and 90% confidence intervals for aripiprazole parameters AUC and Cmax relative to reference values among various special populations. The populations compared include CYP2D6 metabolizer status, gender, age groups, degrees of hepatic impairment, and severe renal impairment.*

FDA Label Image

Figure 5 (Aripiprazole Figure5)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' illustrating changes in AUC and Cmax relative to reference for various subgroups: CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis represents change relative to reference from 0.5 to 3, with data points and confidence intervals shown.*

FDA Label Image

Structure (Aripiprazole Str)

Chemical structure of Aripiprazole, depicted with its distinctive aromatic rings, chlorine substituents, and nitrogen-containing groups consistent with the generic drug composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.